Financings - Articles - Page 26

Microscope with laptop displaying histology image.

Cardiovascular

Thryv Therapeutics advances SGK1 inhibitors for atrial fibrillation and anaplastic thyroid cancer

June 7, 2023

Thryv Therapeutics Inc. has announced the closing of a $5 million convertible note investment, the proceeds of which will be used to accelerate development of its pipeline, including preclinical programs in anaplastic thyroid carcinoma and atrial fibrillation.

Colorized scanning electron microscope image of regulatory T cells and antigen-presenting cells.

Immune

Dualyx completes series A financing to advance Treg therapies for autoimmune diseases

May 15, 2023

Dualyx NV has completed a €40 million (US$44 million) series A financing, allowing the company to advance its lead autoimmune program, DT-001, as well as its pipeline of regulatory T-cell (Treg) candidates.

Drug Design, Drug Delivery & Technologies

Launch of Initial Therapeutics with a focus on selective termination of protein synthesis

May 2, 2023

Initial Therapeutics Inc. has launched with a focus on developing medicines that block difficult-to-drug protein targets with a new mode of action – selective termination of protein synthesis (STOPS).

Inflammatory

Series A financing at Therini Bio funds fibrin-targeted therapies for neurodegenerative and retinal diseases

April 28, 2023

Therini Bio Inc. has closed a US$36 million series A financing round that will support its work on developing fibrin-targeted therapies for diseases driven by chronic inflammation, including Alzheimer’s disease, multiple sclerosis and retinal diseases such as diabetic macular edema.

Cancer

Albatroz Therapeutics secures funding to develop therapeutic antibodies to treat solid tumors and arthritis

April 26, 2023

Albatroz Therapeutics Pte Ltd. has secured $3 million in funding to accelerate the development of therapeutic antibodies against a novel target that degrades the extracellular matrix, a key contributor to cancer and arthritis.

Microscopic view of of high grade urothelial carcinoma of the ureter in a man.

Cancer

Flare Therapeutics announces financing to fund work targeting novel transcription factors

March 23, 2023

Flare Therapeutics Inc. has announced a US$123 million series B financing to support its work targeting novel transcription factors for cancer and other diseases.

Neurology/Psychiatric

Series A financing at Teitur Trophics to fund neurodegenerative disease pipeline

March 14, 2023

Teitur Trophics ApS, a spinout from Aarhus University seeded by the Bioinnovation Institute in 2020, has completed a €28 million (US$30.1 million) series A financing. Teitur has developed a platform of first-in-class cyclic peptides with a novel mechanism that preserves neuronal function, and these peptides have the potential to treat a broad range of neurodegenerative diseases.

Immune

Thymmune Therapeutics raises funding to advance thymic cell therapies

March 2, 2023

Thymmune Therapeutics Inc. has secured US$7 million in seed financing to support its work in developing scalable thymic cell therapies to restore immune function in aging and disease.

A microscopic image of liver tissue affected by metabolic dysfunction-associated steatotic liver disease.

Endocrine/Metabolic

Seed funding at Resalis to support development of ncRNA-based therapeutics for metabolic disease

Feb. 23, 2023

Resalis Therapeutics Srl has completed a seed financing round of €10 million (US$10.6 million) to establish a noncoding RNA (ncRNA)-based...

Illustration demonstrating muscle contraction in amyotrophic lateral sclerosis.

Neurology/Psychiatric

Cerevance expands series B financing to advance therapeutics for CNS diseases

Feb. 14, 2023

Cerevance Inc. has expanded its series B financing with an additional close of US$51 million, bringing the total series B financing to US$116 million. The proceeds will be used to advance Cerevance's therapeutics for central nervous system (CNS) diseases developed using its proprietary Nuclear Enriched Transcript Sort sequencing (Netsseq) platform.

Financings, BioWorld Science
RSS

Thryv Therapeutics advances SGK1 inhibitors for atrial fibrillation and anaplastic thyroid cancer

Dualyx completes series A financing to advance Treg therapies for autoimmune diseases

Launch of Initial Therapeutics with a focus on selective termination of protein synthesis

Series A financing at Therini Bio funds fibrin-targeted therapies for neurodegenerative and retinal diseases

Albatroz Therapeutics secures funding to develop therapeutic antibodies to treat solid tumors and arthritis

Flare Therapeutics announces financing to fund work targeting novel transcription factors

Series A financing at Teitur Trophics to fund neurodegenerative disease pipeline

Thymmune Therapeutics raises funding to advance thymic cell therapies

Seed funding at Resalis to support development of ncRNA-based therapeutics for metabolic disease

Cerevance expands series B financing to advance therapeutics for CNS diseases

Today's news in brief

SCAN is core circuit affected in Parkinson’s disease

First-in-class pan-inflammasome blocker for hidradenitis suppurativa

RX-10616 improves radiotherapy efficacy in HNSCC

CROI 2026: Neurodegeneration, the challenge of aging with HIV

Financings, BioWorld Science RSS

Financings, BioWorld Science
RSS